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IMPROVING PHARMACOVIGILLANCE QUALITY MANAGEMENT SYSTEM IN THE PHARMACY AND
POISONS BOARD OF KENYA
E. Apiyo1, Z. Ekeocha2, S. Byrn3, K. Clase4 
ABSTRACT
The purpose of this study was to explore ways of improving the pharmacovigilance quality system employed by
the Pharmacy and Poisons Board of Kenya. The Pharmacy and Poisons Board of Kenya employs a hybrid system
of pharmacovigilance that utilizes an online system of reporting pharmacovigilance incidences and a physical
system, where a yellow book is physically filled by the healthcare worker and sent to the Pharmacy and Poisons
Board for onward processing. This system, even though it has been relatively effective compared to other systems
employed in Africa, has one major flaw. It is a slow and delayed system that captures the data much later after
the fact and the agency will always be behind the curve in controlling the adverse incidents and events. This
means that the incidences might continue to arise or go out of control. This project attempts to develop a system
that would be more proactive in the collection of pharmacovigilance data and more predictive of pharmacovigilance
incidences. The pharmacovigilance system should have the capacity to detect and analyze subtle changes in
reporting frequencies and in patterns of clinical symptoms and signs that are reported as suspected adverse drug
reactions. The method involved carrying out a thorough literature review of the latest trends in pharmacovigilance
employed by different regulatory agencies across the world, especially the more stringent regulatory authorities.
A review of the system employed by the Pharmacy and Poisons Board of Kenya was also done.
Pharmacovigilance data, both primary and secondary, were collected and reviewed. Media reports on adverse
drug reactions and poor-quality medicines over the period were also collected and reviewed. An appropriate
predictive pharmacovigilance tool was also researched and identified. It was found that the Pharmacy and Poisons
Board had a robust system of collecting historical pharmacovigilance data both from the healthcare workers and
the general public. However, a more responsive data collection and evaluation system is proposed that will help
the agency achieve its pharmacovigilance objectives. On analysis of the data it was found that just above half of
all the product complaints, about 55%, involved poor quality medicines; 15% poor performance, 13% presentation,
8% adverse drug reactions, 7% market authorization, 2% expired drugs and 1% adulteration complaints. A




poor quality medicines,adverse drug reactions, counterfeit medicines,risk
1. INTRODUCTION 
The project involved the strengthening of the quality 
systems for the pharmacovigilance in the Pharmacy 
and Poisons Board of Kenya. The system proposed a 
data driven system that that would be more proactive 
in the collection of pharmacovigilance data and more 
predictive of pharmacovigilance incidences. The 
Pharmacy and Poisons Board of Kenya employed a 
hybrid system of pharmacovigilance that utilized an 
online system of reporting and a physical system 
where a yellow book was physically filled by the 
healthcare worker and sent to the Pharmacy and 
Poisons Board for onward processing. The previous 
system was slow and not quite effective in meeting 
the challenges of a modern pharmacovigilance 
system. There was poor coordination between the 
different departments in the Pharmacy and Poisons 
Board that were meant to use and act on this 
pharmacovigilance data to ensure safety and efficacy 
of registered medicines in the Kenyan market. These 
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3 sbyrn@purdue.edu; Biotechnology Innovation and Regulatory Science (BIRS) Center; Industrial and Physical Pharmacy,
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2
departments were the Medicines and Registration
department, the GMP department, the
Pharmacovigilance department and the Import/Export
department. However, they often times worked
independently of each other and no real time data was
shared among them.For example the
Pharmacovigillance department might receive a
critical information that affects the quality of a product
in the market, if this information is not shared with the
Medicines and Registration department no regulatory
action related to the registration status of the product
will be taken such as deregistration or GMP
inspection of the manufacturing facility. This made
pharmacovigilance very reactive, causing a lot of back
log. The project, as a result, sought to improve the
system so that it could be more proactive than its
current reactive nature. It also looked to enhance the
coordination between the Medicines Registration
department and Pharmacovigilance department and
enhance the involvement of pharmaceutical
manufacturers and distributors in the
pharmacovigilance system.
Poor pharmacovigilance of medicines in Kenya will
result in poor health outcomes for the general public,
such as increased morbidity, poor quality of life and
reduced lifespan for the people of Kenya.
Borg et al. (2011) defined pharmacovigilance as the
science of, and activities relating to, the detection,
assessment, understanding and prevention of
adverse effects of marketed medicines; specifically,
taking action to increase product benefits and reduce
their risks. This is achieved by monitoring the use of
medicines in normal conditions of use to identify
previously unrecognized adverse effects or changes
in patterns of adverse effects.
In 2014, Thompson, Komparic and Smith noted that
once products are approved by regulatory authorities
and used by the public in the uncontrolled context, it
becomes very difficult for the responsible regulatory
bodies to ensure their safety and effectiveness. As a
result, regulation of pharmaceuticals and vaccines
moved towards an approach that considered the full
life cycle of the drug or vaccine. Therefore, new
strategies are being developed to allow faster
identification of high-risk interactions between
marketed drugs and adverse events to enable the
automated uncovering of scientific evidence behind
them. Pharmacovigilance plays an important role in
healthcare through assessment, monitoring and
discovery of interactions amongst drugs and their
effects in human beings. Post market
pharmacovigilance complements the traditional
premarket austere drug approval process where the
National Regulatory Agencies establish guidelines for
new medicine approvals.
According to Lopes et al. (2013), pharmacovigilance
research is based on the analysis of “signals.” The
World Health Organization (WHO) defines signals as
undisclosed assertions or direct relationships
between adverse events or effects on a human
organism and a drug. To generate comprehensive
signal data sets, clinicians and researchers use
spontaneous reporting systems (SRS). Although drug
companies are required to track and manage adverse
events reported by clinicians or patients, the detection
process mostly relies on the physician’s ability to
recognize a given trait as a drug’s adverse event. This
normally results in underreporting and biased
selective reporting.
Labodie (2012) noted that counterfeit or adulterated
drugs have less therapeutic efficacy than the original
product, even when they do not result in additional
adverse reactions. However, when they do result in
adverse reactions, identification of those adverse
reactions, as a first indication of possible counterfeit
or adulterated drugs, requires a well-organized and
rigorous post market surveillance system at the
national level. The pharmacovigilance system should
have the capability to detect and analyze subtle
changes in reporting frequencies and in patterns of
clinical symptoms and signs that are reported as
suspected adverse drug reactions.
The latest trends in the pharmaceutical industry
strongly support the concepts of risk management
and see formal risk management as playing a major
role in the development of safe medicines for the
public, as well as providing a mechanism to ensure
that decisions concerning individual drug benefit and
risk are made based on scientific evidence. Safe
medicines refer to those drugs whose benefits have
been found to outweigh their risks when they are used
according to approved labeling. Risk management is
the comprehensive and proactive application of
scientifically based methodologies to identify, assess,
communicate and minimize risk throughout the life
cycle of a drug so as to establish and maintain a
favorable benefit-risk balance in patients (Bushet al.,
2005).
A key factor in the success of overall risk
management is the dialogue between industry and
regulators throughout the development, review and
marketing of the product. It is through such dialogue
that appropriate, efficient and effective risk
management strategies will be developed and
implemented. Pharmacovigilance has evolved over
time because of increased public awareness of the
potential risks of drug therapy through technology
(such as the internet), globalization of the industry and
changes in the industry. Consumers and media
houses have come to expect “risk free” medications,
 
 
        
       
       
     
     
       
       
        
      
      
        
       




         
       
          
        
       
     
     
       
        
     
       
       
       
       
        
       
        
       
        
 
3
putting pressure on the regulators and industry alike
to ensure that pharmaceuticals “do no harm.”
Globalization has resulted in the need to
communicate with multiple regulatory bodies,
simultaneously, although the individual regulators
may have different perspectives and requirements. As
a result, regulators have increasingly placed greater
importance on the issue of benefit-risk balance of
pharmaceutical products, including greater focus on
recognizing and, where possible, mitigating risks.
Consequently, there is need to improve the current
passive system of post marketing surveillance, which
depends on a voluntary spontaneous reporting
system.
2. METHODS
The methodology involved a review of the poor quality
reports submitted to the Pharmacy and Poisons
Board for the year 2015 in order to classify them
based on a risk-based system. The techniques and
tools utilized in the project included observations,
recordings, document reviews, expert interviews,
focused group discussions, interviews and
questionnaires. The method involved carrying out a
thorough literature review of the latest trends in
pharmacovigilance employed by different regulatory
agencies across the world, especially the more
stringent regulatory authorities. A review of the
system employed by the Pharmacy and Poisons
Board of Kenya was also done. Pharmacovigilance
data, both primary and secondary, were collected and
reviewed. Media reports on adverse drug reactions
and poor-quality medicines over the period were also
collected and reviewedThe data was then analysed
and presented in the tubular form below.
                 
           
   
 
      
    
    
   
   
    
 
   
   
  
  
   












   
   
    
     
     
    
 





     
    
     
  
    
  
 
Table 1. Summary of Pharmacovigillance data obtained from the Pharmacy and Poisons Board for the year 2015.
NO. PRODUCT NAME ACTIVE INGRIEDIENTS NATURE OF COMPLAINT ACTION TAKEN CLASSIFICATION
1 Aloha Liquid
200ml
The product was found
to have turned from
reddish brown to green
and sedimented.
Asked to provide





















Memo to be retrieved
and sent to drug Reg
and to be provided with
a sample of the
photographs.memo





Cotrimoxazole The product had two
layers, an upper light
layer & darker layer at
the bottom-





 4   Morphine HCL
 BP/PH.EUR
Powder 
   Morphine HCL BP
Powder 
   Once the powder is 
  reconstituted with
   distilled water, it forms 
   a solution which starts 
   sedimenting after some
 time.-
   Clarify with the
   reporter. Abdi to be 
   sent to the site. 
 Quality
 5  Heparin Sodium 
Fresenius 
 Heparin Sodium    Four Patients had
   severe reactions on
   administration , ranging
  from headache,
  shivering, body
  weakness, tremors,
  erythematous wheal at 
   injection site. The
    patients did not react to 
  different batch of 
  heparin procured
   thereafter. See yellow
 forms submitted.- 
     Wrote a letter to the
   company and gave
    reportt that we have,
 awaiting response. 
ADR 
 6  Sulfran
suspension 
Cotrimoxazole    Black particles formed
    on shaking the bottle
   and observing under
 sunlight-  
   Sent to NQCL for 
 analysis 09/02/2015 
 Quality
 7  Sulfran
suspension 
Cotrimoxazole    Black particles formed
    on shaking the bottle
  and observing under 
 sunlight-  
   Sent to NQCL for 
 analysis 09/02/2015 
 Quality
 8  Sulfran
suspension 
Cotrimoxazole     The bottle turned black-     Sent to NQCL for 
 analysis 09/02/2015 
 Quality
 9 Nevirapine 
 tablets, USP 
Nevirapine    The packing is similar 
    to that of lamivudine
   150mg from the same 
 manufactuer.
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 




  tablets 150mg
  Lamivudine 150mg     The drug has identical
  packaging to
  Nevirapine 200mg from 
   the same manufactuer.
   Thus dispensing the
    wrong drug is possible
  because they are 
 aesthetically similar- 
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 






11   Lamivudine &
Tenofovir 
 Disoproxil
 Fumarate tablets 
  Lamivudine &
 Tenofovir Disoproxil 
  Fumarate
   The product packaging
    is similar to that of 
  lamivudine, Nevirapine,
  & Stavudine tablets 
  from the same 
 manufactuer.
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 
    a sample of the
photographs. 
Presentation 
12  Efavirenz tablets 
600 
 Efavirenz tablets      The reason for the ADR
    was due to change of 
    formulaion. EFV Mfg by
   Macleods was cited as 
   the cause of severe 
  vomiting, dizziness,
   headache, & body
    ache, & when the old 
 formulation was 
   dispensed the client
  was comfortable. This 
     is the EFV Mfg. by
    Strides Arcolab Ltd that
    the patient had been
  taking without
   complaint. Since then
   client is doing well. 
  Communicated to
  NASCOP asked
    NASCOP to share any
   information that they
    have on the product
     03/02/15 Fill it as an
     ADR write to kisii a
  response letter.
ADR 
13  Curamol  Paracetamol     Solid crystal are seen
     at the bottom of the
container. 
    Abwao to write a letter 
     to KEMSA see if they
   have received any
complaint. 
 Quality
14 Cotrimoxazole Sulfran    Tablets cracking & thus 
  separating 30 tablets 
    returned by client. 145
    tablets had not been
     issued to clients & have
   some features. Total
   tabs available 175
quarantined. 
      Sent to GMP ask for a
sample 
 Quality
15  Sulfran   Sulphamethoxazole
Trimethoprim 
   Crystalization. The non
    - umiformity of the
    syrup crystal seen in
 the syrup. 
   Sent to NQCL for 
 analysis 09/02/2015 
 Quality
16  Bupivacaine
  Hydro in
dextrose 
     Not Potent spinal
   blocade not achieved
  after intra-thecal
administration. 
   Sent to NQCL for 






17  Efavirenz tablets 
 600mg
 Efavirenz tablets 
 600mg
  Formulation change
    related to difference in
   Manufactuer. The othe
    formulation is Mfg by
   Macleods and Pt well 
     tolerated . My client a
     male 60 yrs PSC No.
   12,275-5 Km returned
    drugs to clinic because
  of generalised rahes 
  photos sent online 
09/02/2015 
   Fill an ADR form ADR 
18  Curamol  Paracetamol   Crystalization Solid
   crystals have been
   deposited on the
   bottom of the container 
   shaking container did
    not loosen or dissolve
  the crystals.
   Confirm source with the 
   reporter and get
 samples.
 Quality
19  Methylated spirit       Appears to have an
  abnormal colour,
   thickness and smell
   County pharmacist to
 supply update. 
 Quality
20     Tenfovir Disoproxil
  Fumarate &
Lamivudine 
  Similar packaging color 
 (blue) with 
 Tdf/3tc/Efv/& Nvp 
  200mg making it 
   difficult to differentiate
 the products. 
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 
    a sample of the
photographs. 
Presentation 




  Similar packaging color 
    (blue) with Tdf/3tc &
    Nvp 200mg making it
   difficult to differentiate
 the products. 
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 
    a sample of the
photographs. 
Presentation 
22     Nevirapine 200mg     Similar Pack color blue
   with Tdf/3tc/Efv and
    Tdf/ 3tc making it
   difficult to differentiate
 the products. 
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 
    a sample of the
photographs. 
Presentation 
23 Bactoclav-625  Amoxicillin/
 Clavunate
 500/125mg
Substandard   Results received from 
  NQCL 16/04/2015
   Does not Comply
 Quality
24 Bactoclav-625  Amoxicillin/
 Clavunate
 500/125mg
Substandard   Results received from 
  NQCL 16/04/2015









  The formulation has 
      particles in it. It is even
  rough on hand. 
   Sent to NQCL
09/02/2015 
 Quality
26  Efavirenz tablets 
 600mgs
 Efavirenz tablets 
 600mgs
    The client cited change
    of formulation as the
    cause of the ADR.
     when he took his first
   dose of efavirenz
  manufactured by
   strides arcolab limited
 he developed 
   generalized rashes the
   following day. Patient
    returned the drugs and
    demanded for the old
 formulation
  manufactured by
macleods 
  pharmaceutical limited
    which he had used
   since 2006 safely
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 
    a sample of the
photographs. 
ADR 
27 N/A Fluphenazine 
   Deacanoate Inj. BP
 1ml
    The ampoule does not
   contain the 1ml as 
   specified in package
   the ampoule line of 
   weakness is not
   adequate to enable
    opening. At times the
 ampoule breaks 
 inappropriately
   To ask for samples  Quality





    The product should be
     packed in boxes of 100
   packs but all boxes 
   received had 6 packs 
 less.
  Contact pharmacist for 
  more information.to






29     TDF 300Mg/3TC
300Mg 
    The two products very
 similar packages 
  creating alot of 
 confusion when 
   dispensing at facility.
   AT ONE TIME
  3TC/TDF WAS
  DISPENSED INSTEAD
   OF 3TC/NVP/d4t AND
    THE PATIENT HAD TO
    BE CALLED TO COME
  FOR THE RIGHT 
  MEDICATION. THIS
  WAS REALIZED
  BEFORE THE
   PATIENT HAD USED
  THE MEDICATION
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 




  tablets 150mg
  Lamivudine 150mg   The boxes and 
   containers are similarily
   colored and designed.  
   Memo to be retrieved 
    and sent to drug Reg 
    and to be provided with 
    a sample of the
photographs. 
Presentation 
31  Isovent 200  Misoprostol
 200mcg
    There has been a
   number of failed
   inductions with the
product. 
   samples were collected
  on 19/03/2015 from 





 Injection B.P 
 Lidocaine
  Hydrochloride B.P
 1% w/v 
  severe adverse
   reactions at injection
   site upon injection
 ophthalmologist
  reported massive
 oedema (orbital) 
     extending to the face in
    all the patients he
  administered. The
 preparation contains 
  Benzyl alcohol as 
preservative. 
   Is an ADR  ADR 
33   Pure Soya Oil         Need to establish how
    these products get into
   the country.and then
    check with drug reg
  wether they are 
   listed.Then to see
    wether we can enforce
   a crack down.To
  investigate herbmed
   research group to
    confirm where they are





34  Mens Powder 
Power 
   Ginseng root bilora
  ginggigo tonkatail & 
others 
  " MA 
35  B-tex Lotion    Salicylic acid ip
  10% w/v denatured 
   spirit with 1%
  acetone QS alcohol 
 content 80-90% 
 " MA 
36  Broad Spectrum 
  herbal chest (A) 
powder 
    " MA 
37  Broad Spectrum 
  herbal chest (A) 
powder 
   " MA 
38  Anti typhoid 
  Malaria Amoeba
 Herbal Powder 
    " MA 
39  Sapat Plus 
Lotion 
    " MA 
40   Purex Special
 Body Detox 
    Aloe soctrina Urtic ,
   neem a dloca,
   garlic yellow dock,
   senna & yarrow
  " MA 
41 Biodopa   Methyldopa 350mg    Moulding observed on
tablets  
    Inform Biodeal if they
  have any complaints 
    from the market. To
     send out an e-shot to
   check the magnitude of 
   the problem then from 
  the information
    received we can make
 a decision 
 Quality
42 Kinem   Imipenem &
 Cilastatin for 
 injection USP 
    The powder does not
   dissolve completely in
  some vials.In others 
   once the powder
   dissolves the solution
  changes colour from 
   from yellow to dark 
brown. 
   Njeri to Contact
  Regulatory Pharmacist
     of Medox to bring the






43 Dawaflox Flucloxacillin    The above product
  when reconstituted
    forms a clear solution
  with small black 
   particles were seen
  inside reconstituted
product. 
     An e-shot was sent out
  the company
   pharmacist brought a
   recall letter between
    15th -25th of March
    2015. Need to retrace
   that letter from Kabue 
 Quality
44 Dawaflox Flucloxacillin    The above product
  when reconstituted
    forms a clear solution
  with small black 
   particles were seen
  inside reconstituted
product. 
     An e-shot was sent out
  the company
   pharmacist brought a
   recall letter between
    15th -25th of March
    2015. Need to retrace
   that letter from Kabue 
 Quality
45  Normal Saline 
 nasal drops 
  Sodium Chloride
 0.99% w/v 
  Suspected adulteration
     the drug has a strong
   pungent smell similar to 
 organophosphate
   chemicals. The Nasal
 drops were 
   administered to the
   child who developed
   pin point pupils. Find 
  attached documents.
   Get final investigational
  report from Dennis  
Adulteration 
46 Neladol  Paracetamol   Brownish colouration of 
    some tablets in the
  1000tab tin of 
paracetamol 
   Refer to the older 
  investigational report
    for neladol and to
  contact the reporter 
 Quality
47  Salbumed  Salbutamol     The syrup is packaged
  in transparent plastic 
    bottles as opposed to
  the recommended
  amber coloured bottles 
   to protect from sunlight. 
    Check with drug reg
  what they registered 
    and follow up with the 
 company.To confirm 




 Oral suspension 
 Alimox  Colour change.  QSE recommendations  Quality
49  Nepusolone
  Forte eye drops 
Prednisolone 
  Acetate 1.7m/v
    Clouding lack of batch
  No. prescence of 
    particulate matter in the
   eye drops that has 
  caused clouding in 
    what should have been
   a clear solution.  
   inform GMP &
    Inspectorate to do a
     follow up of the same
    and guide them on






  Eye drops BP 
  Miconazole 1% m/v   Clouding crystallisation
    lack of batch No.
 prescence of 
   particulate matter in
   eye drops that has 
  caused clouding in 
    what should have been
  clear cloudy & 
 sedimentation
observed. 
   inform GMP &
    Inspectorate to do a
     follow up of the same
    and guide them on
  GMP issues.
 Quality
51 Nepucortisone 
 eye Drops 
  Hydrochloride base
 PMCO 0.0048 
   Clouding. The product
  showed prescence of 
 particulate matter 
   resulting in clouding
  sedimentatiom &
 caking.  
   inform GMP &
    Inspectorate to do a
     follow up of the same
    and guide them on
  GMP issues.
 Quality
52   Bupivacaine in
 Dextrose
 injection USP 
 Bupivacaine HCL  Diminished potency. 
    The product was found
   to have diminished
  potency effective ness 
   to the extent of 
    requiring a repeat dose
   to achieve spinal
 anaesthesia.-
     to check if they were
    sent to the lab Miriam  
Poor 
 performance




  the product
 effectiveness was 
     found to be lower than
    normal to the extent of 
   needing a repeat dose 
  to achieve
effectiveness. 
  same as above Poor 
 performance
54   Tenolol - 50    Atenolol BP 50mg   Suspected poor quality-    Checked with Drug
  Reg. Its Registered 
13/04/2015 
 Quality
55  Zycet syrup  Cetrizine
  Hydrochloride B.P
 5mg
   Suspected poor quality   Not Registerd
13/04/2015 
 Quality
56  Zycet tablets  Cetrizine
 Hydrochloride
  tablets 10mg
   Suspected poor quality   Not Registerd
13/04/2015 
 Quality Y 
57 Enterezole   Diloxanide Furoate
  B.P 250mg
Metronidazole 
 Benzoate BP 







 Eye/Ear drops 
  Gentamicin Sterile
 10ml
   Suspected poor quality    Checked with Drug
  Reg. Its Registered 
16/04/2015 
 Quality
59   Cipiem Tabkets  Chlorophenaramine
    malelate B.P 4 mg
   Suspected poor quality    Checked with Drug





 Infusion B.P 
     Suspected poor quality    Checked with Drug
  Reg. Its Registered 
16/04/2015 
 Quality  
61 Biomol  Paracetamol     Some tablets had a
 brownish colour 
  pick the previous 
    reports look at the
    batches and make a
decision. 
 Quality
62  Alimox   Amoxicillin Oral
Suspension 
 Suspension changes 
 color when 
  reconstituted caking is 
observed. 
  Implement QSE
recommendations 
 Quality
63  Alimox   Amoxicillin Oral
Suspension 
  Colour change from 
    white to yellow and
 brown when 
recostituted. 
  Implement QSE
recommendations 
 Quality
64  Alimox   Amoxicillin Oral
Suspension 
  Colour change from 
    white to yellow and
 brown when 
recostituted. 
  Implement QSE
recommendations 
 Quality
65  Alimox   Amoxicillin Oral
Suspension 
  Colour change from 
    white to yellow and
 brown when 
recostituted. 
  Implement QSE
recommendations 
 Quality
66 Alfree  Cetrizine
Dihydrocloride 
 The manufacturer 
   describes the tablet as 
    a white oval shaped
    uncoated tablet on one
     side and plain on the
    other side for oral
  administration. We
    however noted that the
    tablets are not white
   but rather creamish
   with yellow crystals.
   Contact the Local
   agent get info from 






67 Kinem   Imipenem &
 Cilastatin for 
 injection USP 
   After adding 10mL of 
  Normal saline as 
  appropriate and
  shaking it vigorously, 
    the solution does not
    mix. the powder quickly
    settles at the bottom of 
   the bottle. ALso
   another bottle received
     from the ward had a
   reddish color instead of 
   white to yellow color. 
   Contact the Local
   agent get info from 
    drug reg on what was 
regeistered 
 Quality
68 Kemoxyl Amoxicillin   Capsules heads breaks 
   off and the contents 
   spills in the container 
   Contact the reporter for 
   samples then get
   intouch with the
   company.confirm if it
   was a government
   tender or private
purchase. 
 Quality
69  Hemsyl Inj   Etamsylate BP 125   Colour change from 
     tinge to brown. only two
  ampoule affected, signs 
    of slow leakage along
   the neck/ scoreline as 
  evidenced by
  comparatively low
    volume of the content
   and mould like
   substances around the
   necks of affected
ampoules. 
    to Call the company on 
  27/05/2015 and ask 




  and TDF/3TC
  and NVP
Tablets 
     The complaint is about 
    the packaging of the
 TDF/3TC/EFV,
   TDF/3TC and NVP
   from this company.
   Their outer packaging
   look very identical. This 
  can cause serious 
  dispensing errors
   especially in busy
  hospital pharmacy
   departments and where
     there are trainees in the
   department. they are
    also very confusing to
   our patients. The color 
   and design of the 
   packaging should be
   changed See the
  pictures attached,
    refer above Cristabel to





    especially the ones on
 the shelves. 
71  Jotomol  Paracetamol    crumbling and breaking
    of tablets into small
  particles and powder 
      a letter to be written to
  be to BENMED 
 Quality
72 Pyremol  Paracetamol
Suspension 
  The syrup has 
   unpleasant smell and
    the labelling is different.
    The same product but
    the other one has faint 
label 
     Call the reporter to give
   us samples.and also
   call Concepts africa Ltd 
 Quality
73 Salol  Salbutamol   Powdering and
crumbling 
  Check registration
   status and ask for 
  samples.Biopharma to
    be sent for a letter 
 Quality
74  Chlorist  Chlorophenaramine
    malelate B.P 4 mg
  Powdering and
crumbling 
   Check the registration
   status and contact
 syner Med. 
 Quality
75 Metopride  Metoclopramide
  injection BP
 10mg/2ml
 THE AMPUOLE 
   NEEDS TO HAVE
  CLEAR SOLUTION
  FOR INJECTION BUT 





  N FROM YOUR 
    OFFICE ON THE WAY
   FORWARD BUT TGE
   AMPOULE HAS BEEN
  QUARANTINED FOR
  THE TIMR BEING. 
    Ask the reporter to
   send samples then we 
  contact the
   company.Get the local
   agent from Drug reg. 
 Quality
76 Heparovit-H  Heparin Injection   The patient
  experienced shivering,
   difficulty in breathing
   and bronchospasms on
   administration on a
   dialysis patient on two 
occasions 
   Should be reported as 
   an ADR Cristabel to 








    THE AMPOULES
  HAVE SOME LEAKING 
   POINTS THAT DRAIN
  GRADUALLY. SOME
  AMPOULES ARE
 COMPLETELY
  EMPTY. THIS
  HAPPENS IN AT 
   LEAST 20-40% OF
 THE AMPS 
    Contact the reporter to
    send samples. Find the
  local distributor.to
  check registration
    status, confirm with the
   reporter if it was 
  supplied by KEMSA 
 Quality
78 Nicardia Nifedipine    Complaints that the
    product is not reducing
  blood pressure.
    Contact the reporter to
    send samples. Find the
  local distributor.to
  check registration
    status, confirm with the
   reporter if it was 
  supplied by KEMSA 
Poor 
 performance
79 Nicardia Nifedipine    Complaints that the
    product is not reducing
 blood pressure.as 
required 
    Contact the reporter to
    send samples. Find the
  local distributor.to
  check registration
    status, confirm with the
   reporter if it was 
  supplied by KEMSA 
Poor 
 performance
80 Dawa-flox Flucloxacillin    Capsules were opened 
    and the powder spilt.
  Some other capsules 
  had different colours 
   Contact supplier &
   reporter to give us 
    samples. Talk to Dr.





 Quinine inj 
 600mcl/2ml
    the quantitiy of the
   drugs is incomplete
    because of the poorly
  packed ampoules.
   contact the company
    and refer the company
   to GMP and check 
   GMP status and check 








   Injection BP 1ml
Fluphenazine 
  Decanoate Injection
  BP 1ml
    The nurses in the
 psychiatric ward 
  reported several cases 
   of patients that
 experienced relapses 
   of psychosis 2 weeks 
  after administration of 
     the drug instead of 4
 weeks.The nurses 
   carried out an
   experiment where they
    issued the same batch
    under question to some
    patients and a different
  brand from another 
   company. Those who
    were given the batch
 under question 
  returned with psychosis 
     while those who got the
   other brand came back 
   on there appointment
    day after 4 weeks.
   Contact the reporter for 
  more information, ask 
  them for samples 
 check registrations 




83   Artesun 120mg  Artesunate injection   full course of 
  artesunate injection
    drug administered to 2
   patients with a positive 
  blood smear for 
   malaria. the MPS after 
   treatment was still
  positive. patients were 
   switched to quinine
   injection and they
 responded well. 
 Registration status 
    Contact them to find if 
  the have samples 
Poor 
 performance
84   Oxytocin 10 i.u   Oxytocin 10 i.u     Low efficacy i.e Using
     up to 4times the normal
   dosages to achieve
  desired results as 
  stored at room 
 temperature.
    Send abwao an email
     to ask him about the
   outcome of the
 oxytocin analysis 
Poor 
 performance
85   Gripe Water Sodium 
Bicarbonate 
  White Floating particles     Ask the reporter to
   provide samples and
  ask the manufacturer 
  for samples.
 Quality
86 Neocuron Pancuronium     The effects wear out
     within a very short time
  (20-25 minutes), higher 
   doses are required.
   Anesthetists have had
     to use doses as high as 
    To ask the reporter for 







   18mg for an operation 
      of two and a half hours.
87   Unitel -H 40   Telmsartan with
HCL 
  Bought Expired drugs 
  from Temple Stores 
  Pharmaceuticals on
30/05/2015 








    After taking meds 
  experienced skin
   rashes & difficulty
  breathing feeling
  exhausted.Expired drug
    was given to patient
    boss. After finishing the
     dose the client went to
    hospital after which he
     was told to report to
PPB 
  ADR 
89 Apresoline  Hydrlazine Injection   The powder for 
 reconstitution has 
  changed color from 
    yellow to white, the
    product has caked at
    the bottom of the
   ampule and the
  resultant powder after 
    intensive shaking of the
    ampule is not free
flowing. 
    to contact reporter to
    bring sample and to
  also contact
   manufacturer to bring
sample 
 Quality
90 Parace  Paracetamol   The tablets crumbles 
   /breaks easily into
pieces. 
  To registration status 
   and get samples from 
reporter 
 Quality
91  Dawa flox Flucloxacillin 
 125mg/5ml powder 
 for suspension 
   Particular bottles of the 
   said batch started
    caking & color change
    from white to pink.
     we will sample for more
     and sent an e-shot to




 Diclofenanc Inj     The drug has changed
     in color i.e to pink color 
   To confirm registration
   status and act from 
  there.Call the reporter 
    to fill a yellow form, 
   quarantine the product
     and then hand over the
  case to inspectorate 
 Quality
93  Bupivacaine
  HCL dextrose
injection 
  Bupivacaine HCL
 dextrose injection 
    The product does not
  achieve optime levels 
   of anaesthesia @
 therapeutic doses 




94 Tenoretic       Sold for expired drug
    from on 8th July 2015 
    Inspectorate to give an





 KONTRAC 200 
 Misoprostol
 200mcg
   Lack of efficacy   Poor 
 performance
96 Hepa  Heparine 5000iu    There is coagulation
   despite increase in
   dosage of the drug. 
   Take to NQCL for 
 analysis 04/08/2015 
Poor 
 performance
97 Ceftriaxone  Ceftrimed    Patient on treatment for 
  severe UTI.put on 
   ceftriaxone 1gm of for 
 5/7.developed itchiness 
    mild on day one of 
  treatment and was 
reassured..has 
   developed type 1
 hypersensitivity
   reaction after finishing
 dose ..1later.patients 
 has swollen 
  face..periorbital edema
  and wheels....over the 
  whole body.patient has 
  associated intense
  itchiness which results 
  to wheals after 
scratching. 
    Reporter to be advised
    to fill a yellow form 
 ADR form 
ADR 
98 Aziagio    Overwhelmingly
   Repugnant spicy smell,
   coarse consistency and
   bitter pepperminty taste
   with a strong after-
  taste. Induces vomiting 
    almost instantly even to
   a normal adult.
  Absolutely unpalatable
  for paediatric patient 
    to call the reporter ask 
     for sample and ask the











 AND PRODUCT 
  COMPOSITION IS
  UNREGISTERED. HAS
 TERBUTALINE
  SULPHATE IP 1,25MG 
  INSTEAD OF
SALBUTAMOL 
   SULPHATE BP 2MG.
   Inspectorate to do






     IT DOES NOT HAVE A
   UNIT BOX OR PIL 
100 Dolomol Dolomol    The tablets have
   changed colour to
brown 
     To ask for samples and
    to send an eshot and 
     get in touch with the
 supplier or 
 manufacturer.
 Quality
101  Nimodor -s   Sufadoxine 500mg
 Pyrimethamine
 25mg
     The tablets are said on
    the label to be film 
    coated while in actual
   sense they are
   uncoated. Plus there is 
    no literature for the
   product or any other 
  information apart from 
     the sticker on the tin.
    The tablets look like
    any other circular tablet
   with no engraving for 
   identification and the
   description states that
   its film coated while 
   onnchechikng they are
  uncoated white circular 
tablets 
   Get samples contact
     the agent Look at the
   submitted dossier on
  what was suggested. 
 Quality
102 Dolomol  Paracetamol Moulding      To ask for samples and
    to send an eshot and 
     get in touch with the
 supplier or 
  manufacturer Edward
     to do the eshot Mary to 
 follow up. 
 Quality
103 Hepa    Heprin Sodium BP
5000iu 
     The drug was found to
   be in-effective. Blood
  coagulation took place 
   during dialysis despite
    it being administered in
  correct doses.
     To follow up with the
 lab NQCL 
Poor 
 performance
104 Biodopa    Methyldopa 250 Mg
Tablets 
   The yellow tablets form 
     moulds and turn to grey
 in colour 
     Abwao to do an eshot
   and find out from 
     KEMSA if there is a
   report on the
   same.Mary to contact









    The drug RHZE turned
    dark brown from brown
   and crumbling happen
      to a whole row in a
   pack. Patient complaint
    in change of test, feels 
      as if has not taken any
  medicine (different from 
  other similar medicine 
   Edward called on
   23/09/2015 To ask for 
     samples so that we can
   send them for analysis 
 Quality
106  Telmi 80H   Telmisattan 80mg
 Hydrochlorothiazide
 12.5mg tablets 
  The medicine
disintegrate/dissolves 
 before swallowing 
   Sent to NQCL
04/08/2015 
 Quality
107 Cytotec  Misoprostol
 200mcg
  Suspected potency
  issue one mother 
  experienced raptured
   uterus and the other 
   one had precipitate
    labour is still born birth. 
     To liaise with Drug reg
    Dr Mbwiri and ministry
  of reproductive health  
Poor 
 performance
108   Depin E Retard   Nifedipine Retard
 Tabs
 Batch
  No.Manufacturing date
   and Expiry date of 
 product omitted. 
    write am email to
   MEDS Get Kingori to 
    dispatch a team to
    quarantine and give the
     quantities and to give a
    list of all the places 
supplied. 
 Quality
109  Not Indicated  Not Indicated   The product was 
   packed together with
 Diclofenanc tablets 
   50mg but not labelled 
    write am email to
   MEDS Get Kingori to 
    dispatch a team to
    quarantine and give the
     quantities and to give a
    list of all the places 
supplied. 
 Quality
110 Cytotec  Misoprostal tablets 
 200mcgs
       It is a follow up of the
    ADR that was reported
 on 31/07/2015 
   To contact Ministry of 
 Reproductive Health. 
ADR 
111  OXYTOCIN
 INJECTION BP 
 OXYTOCIN    There was several
 complaints from 
    maternity ward that the
    drug failed to produce
   the desire effect
   (induction of uterine
contraction) 
    Dr. Kimathi Draft a
    letter to the registrar for 
   change in storage
   conditions. To liaise







 Sulphate Tablets 
      The tablets are dull red 
    instead of the usual
     bright red, they break in
   the mouth like chalk 
     which is not what I am 
     used to. I feel dizzy
   upon taking them which 
   is odd. Something is 
  just not right. 
   Edward contacted the
   reporter and they were 
    to organise on how
   they can collect the 
   samples from the
hospital 
 Quality
113   Bupivit - D  Bupivacaine
  Hydrochloride in
 Dextrose injection 
    After spinal injection it
    does not pick, most of 
     the time it fails and if 
    lucky it picks it gives 
   more hypotension than
  the block intended. 
  The product passes 
     analysis so we to Write
     to the owner of the
  product/agents to
  explain the problem 
    followed by a literature
  review contract experts 
   to analyse the product. 
Poor 
 performance
114 Metropride  Metoclopramide
  injection BP
 10mg/2ml
   The liquid in the 
  ampuoles have
   different colors, some
   colorless, some are
    bluish green. This may
   indicate that there is 
  some color change. 
   Quality
115 Carefenac Diclofenanc 
 Sodium Inj 
   Ampoules not labelled.
   Severe discomfort on
   injection (severe pain
    redness & swelling) at
   the site of injection. 
  Presentation 
116  Diclomed  Diclofenac Sodium   Packs contain
  ampoules with d
  colours of solutio
 Clear yellow. 
 ifferent
  n i.e




 Hartmann's Soln      Black growths spotted
    in the colourless soln
 supposedly having 
  grown overtime
  suspected to be 
 moulds.







        
 
              
                 
                
               
              
                
                     





Regulatory Pharmacovigilance Prioritisation System (RPPS) refer to appendix.
A Regulatory pharmacovigillance prioritization system adopted from Seabroke et al. (2013) was developed. This
tool is prposed for adoption by the Pharmacy and Poisons Board Pharmacovigillance department. It is a risk-based
system that implements regulatory action based on a weighted system, as shown in Table 2 below.
The tool reviews different sources of pharmacovigillance information and weights them depending on their impact
on their importance. The different categories are regulatory obligations, public health implications, strength of
evidence and public perceptions. Input is the source of the pharmacovigillance data. Criteria for a positive
response in the RPPS tool indicates the severity of the adverse effect and the number of points is the weight given
to the criteria.
Table 2.
































Estimated number of patients prescribed medication in 
the past 
year in Kenya is[100,000 or the drug is newly marketed 
but 
   with the potential for rapid uptake
   Absolute frequency of the ADR is thought to be at least 
1/1,000 
users 
Combined case fatality rate plus non-fatal outcome 
 score in Impact
Analysis is 0.7 or greater 
In total, more than 20 cases or three fatalities have 
been reported 
 spontaneously in Kenya 
      The Cabinet Secretary of Health or Ministry of Health 
has expressed concern 
 about the drug or sent significant correspondence in the 
last 
12 months 
 Parliamentary questions relevant to the safety of the 
drug have 
  been posed in the last 12 months
  Kenya is rapporteur or reference member state for the
drug 
An application from the Marketing Authorisation Holder 
 has some
    bearing on the issue, e.g. an application to reclassify
 from a


















































 An EBGMb[10 (spontaneous ADR data) and/or RR[3 
 (RCT or
 epidemiological study) has been observed 
More than one data source provides positive clinical 
evidence of a 
hazard (e.g. spontaneous ADR data plus an 
observational study) 
  At least some positive evidence comes from a RCT or
metaanalysis 
There is some biological plausibility for the ADR 
 There has been significant media attention for the drug 
in the last 
12 months 
 Two or more factors in the following list are present: 
 •  ADR threatens death (C5 % case  fatality in 
spontaneous ADR 
data) 
• ADR threatens vulnerable groups (e.g. children, 
pregnant 
 women)
     • ADR is generally unavoidable by taking precautions 
(few clear 
 risk factors, no specific monitoring) 
• ADR involves   cancer, teratogenicity,   suicidality or 
major 
 neurological disability
• Scientific basis for ADR is  poorly understood (no 
known 
biological plausibility) 
     • Experts have publicly disagreed about the existence 
or scale of 
the problem 
  • New first-in-class drug where the safety profile is not 
yet 
established 
 Potential public misperceptions about the safety of the 
drug could 
be expected to cause harm through a behavior change 
(e.g. 
decreased vaccine uptake, abrupt discontinuation of 
medicine) 
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3. RESULTS AND DISCUSSION
Based on the data collected in Table 1, it was noted
that the current pharmacovigilance system utilized by
the Pharmacy and Poisons Board collected
numerous data relevant to pharmacovigilance. On
analysis of the data it was observed that just above
half of all the product complaints, approximately
55%, involved poor quality medicines, 15% on poor
performance, 13% on presentation, 8% on adverse
drug reactions, 7% market authorization, 2% expired
drugs and 1% adulteration complaints. This was
good information; however, it did not give guidance
on the next step to be carried in order to reduce or
mitigate these pharmacovigilance incidences. A new
system, Regulatory Pharmacovigilance Prioritization
System, adapted from Seabroke et al. (2013) was
proposed to be implemented to develop regulatory
action as a result of these pharmacovigilance
incidences. The tool was deemed appropriate since
it utilized a weighted risk-based system, as shown in
Table 2, to determine regulatory action. This tool took
into account, not only the current pharmacovigilance
parameters recorded by the system, but also
included public health implications such as drug
exposure, recent parliamentary questions, marketing
authorization, public anxiety and misperceptions and
other concerns, which are not captured in the current
system. The weighting of the pharmacovigilance
incidence will help the agency make decisions on
how to handle the pharmacovigillance incidences.
The higher the weight the more effort need to be put
in place to mitigate or prevent such future
occurences. This will make the system more
proactive and responsive in regulatory actions.
4. CONCLUSION
This project gives the Pharmacy and Poisons Board
a new tool that it could use to improve
pharmacovigilance of medicines in the Kenyan
market. The tool uses a risk-based system to weight
and prioritize different pharmacovigilant relevant
signals that could be used to make regulatory
decisions and actions. This system is definitely more
proactive and responsive to the needs of the public
whose safety pharmacovigilance is supposed to
protect.
5. RECOMMENDATIONS FOR NEXT STEPS
The next step would be to implement the Regulatory
Pharmacovigilance Prioritization system. Since the
system incorporates pharmacovigilance signals that
are currently not captured, such as public health
implications, public perceptions, media perceptions,
recent parliamentary questions, etc., it would be
necessary to redesign the pharmacovigilance
information collection system to take these factors
into account. The tool should be redesigned to reflect
the current needs and capabilities of the Pharmacy
and Poisons Board. The tool is in the form of a flow
chart however it can be adapted into a mobile phone
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